News
Article
Author(s):
CBM’s plasmid manufacturing offering is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.
The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization, announced the launch of its plasmid manufacturing offering, Precision Plasmids, on Feb. 2, 2023. The service is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.
According to a company press release, the service uses next-generation sequencing to guarantee reproducibility of vector-based therapies that are manufactured using plasmids. Expected turnaround times are 12 weeks for plasmids from a good manufacturing practice (GMP) master bank, or 17+ weeks for those working from a starting R&D plasmid.
“As a starting material for mRNA [messenger RNA] vaccines and key components for vector-based cell and gene therapies, plasmids are in high demand for the foreseeable future,” said Dana Cipriano, senior-vice-president, Testing and Analytical Services & Plasmids, CBM, in the release. “CBM’s Precision Plasmids solve the capacity challenge by bringing a platform process, multiple scales, and segregated suites to meet any clinical and commercial production needs on demand.”
The plasmids are offered in three varieties: R&D, Pro, and GMP. The R&D plasmids grade for pre- and early clinical phases, while the Pro grade for toxicology studies, Phase I to II vector production, or as a starting material for mRNA. GMP grade services are expected to launch in April 2023.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.